Astellas Pharma Inc.

Astellas Pharma Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of March 31, 2025, Astellas Pharma Inc. has 1.79B shares outstanding.

As of March 31, 2025, Astellas Pharma Inc. maintains a current ratio of 1.13, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2025.

Over the twelve months ended March 31, 2025, Astellas Pharma Inc. recorded an income tax benefit of -2.10B rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 8, 2026, Astellas Pharma Inc.'s stock has gained approximately 25.39% over the past 52 weeks.

As of March 31, 2025, Astellas Pharma Inc. holds 29.78B in cash and equivalents against 113.41B in total debt, resulting in a net debt position of 87.71B. Total book value stands at 206.41B, with working capital of 19.06B providing operational flexibility.

These figures cover the twelve months ended March 31, 2025.

Astellas Pharma Inc.'s most recent stock split took place on March 27, 2014 with a 1:5 split ratio.